Telix Pharmaceuticals Limited ADR (TLX)

$8.10 +0.01 (0.12%)
Market Cap 2.74B
Revenue (ttm) 516.68M
Net Income (ttm) 32.93M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE 57.50
Profit Margin 6.37%
Debt to Equity Ratio 1.00
Volume 92,900
Avg Vol 125,780
Day's Range N/A - N/A
Shares Out 338.72M
Stochastic %K 22%
Beta N/A
Analysts Strong Sell
Price Target $21.80

Company Profile

Telix Pharmaceuticals Limited, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic and diagnostic radiopharmaceuticals. The company operates through three segments: Precision Medicine, Therapeutics, and Manufacturing Solutions. Its lead therapeutic product candidate is TLX591, a lutetium-labeled radio antibody-drug conjugate (rADC), which is in a Phase 3 clinical trial in patients with advanced prostate cancer. The company develops TLX250...

Industry: Biotechnology
Sector: Healthcare
Phone: 61 3 9093 3855
Address:
55 Flemington Road, Level 4, North Melbourne, Australia
Latest News on TLX
TLX LAWSUIT DEADLINE: Hagens Berman Urges Telix Investors to Act by Jan. 9 Over Alleged Dual Regulatory Failures: SEC Subpoena & FDA CRL on CMC/Supply Chain

Dec 23, 2025, 1:12 PM EST - 1 day ago

TLX LAWSUIT DEADLINE: Hagens Berman Urges Telix Investors to Act by Jan. 9 Over Alleged Dual Regulatory Failures: SEC Subpoena & FDA CRL on CMC/Supply Chain

TLX INVESTOR NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Telix Pharmaceuticals

Dec 22, 2025, 10:02 AM EST - 2 days ago

TLX INVESTOR NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Telix Pharmaceuticals

Precision Medicine Portfolio Update: Illuccix China Phase 3 Study, TLX101-CDx and TLX250-CDx FDA Resubmissions

Dec 21, 2025, 4:38 PM EST - 3 days ago

Precision Medicine Portfolio Update: Illuccix China Phase 3 Study, TLX101-CDx and TLX250-CDx FDA Resubmissions

TLX INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Telix Pharmaceuticals

Dec 19, 2025, 9:43 AM EST - 5 days ago

TLX INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Telix Pharmaceuticals

Shareholders who lost money in shares of Telix Pharmaceuticals Ltd. (NASDAQ: TLX) Should Contact Wolf Haldenstein Immediately

Dec 16, 2025, 3:30 PM EST - 8 days ago

Shareholders who lost money in shares of Telix Pharmaceuticals Ltd. (NASDAQ: TLX) Should Contact Wolf Haldenstein Immediately

UPCOMING DEADLINE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Telix Pharmaceuticals

Dec 15, 2025, 10:40 AM EST - 9 days ago

UPCOMING DEADLINE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Telix Pharmaceuticals

INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Telix Pharmaceuticals

Dec 11, 2025, 10:20 AM EST - 13 days ago

INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Telix Pharmaceuticals

Telix and Varian Announce Strategic Theranostics-EBRT Clinical Collaboration

Dec 10, 2025, 7:00 AM EST - 14 days ago

Telix and Varian Announce Strategic Theranostics-EBRT Clinical Collaboration

Telix Pharmaceuticals (TLX) Sued After Alleged Misstatements on Prostate Cancer Drug Progress and Supply Chain Reliability – Hagens Berman

Dec 2, 2025, 5:17 PM EST - 22 days ago

Telix Pharmaceuticals (TLX) Sued After Alleged Misstatements on Prostate Cancer Drug Progress and Supply Chain Reliability – Hagens Berman

Telix Pharmaceuticals (TLX) Sued After Alleged Misstatements on Prostate Cancer Drug Progress and Supply Chain Reliability-- Hagens Berman

Nov 28, 2025, 5:25 PM EST - 26 days ago

Telix Pharmaceuticals (TLX) Sued After Alleged Misstatements on Prostate Cancer Drug Progress and Supply Chain Reliability-- Hagens Berman

Bragar Eagel & Squire, P.C. Reminds Investors of Telix Pharmaceuticals and Firefly Aerospace to Contact the Firm About their Rights Before Lead Plaintiff Deadlines

Nov 28, 2025, 11:44 AM EST - 26 days ago

Bragar Eagel & Squire, P.C. Reminds Investors of Telix Pharmaceuticals and Firefly Aerospace to Contact the Firm About their Rights Before Lead Plaintiff Deadlines

FLY

The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of January 9, 2026 in Telix Pharmaceuticals Ltd. Lawsuit - TLX

Nov 24, 2025, 8:45 AM EST - 4 weeks ago

The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of January 9, 2026 in Telix Pharmaceuticals Ltd. Lawsuit - TLX

TLX INVESTOR REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Telix Pharmaceuticals

Nov 23, 2025, 6:18 AM EST - 4 weeks ago

TLX INVESTOR REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Telix Pharmaceuticals

ZIRCON-X Analysis: TLX250-CDx Impacts Clinical Decision Making for Almost Half of Patients with Indeterminate Renal Masses

Nov 19, 2025, 2:00 PM EST - 5 weeks ago

ZIRCON-X Analysis: TLX250-CDx Impacts Clinical Decision Making for Almost Half of Patients with Indeterminate Renal Masses

Telix to Participate in UBS and Jefferies Global Healthcare Conferences

Nov 5, 2025, 6:00 AM EST - 7 weeks ago

Telix to Participate in UBS and Jefferies Global Healthcare Conferences

Telix Pharmaceuticals Limited Investigated by the Portnoy Law Firm

Oct 23, 2025, 2:08 PM EDT - 2 months ago

Telix Pharmaceuticals Limited Investigated by the Portnoy Law Firm

Telix Doses First Patient in SOLACE Trial for Metastatic Bone Pain

Oct 22, 2025, 4:00 PM EDT - 2 months ago

Telix Doses First Patient in SOLACE Trial for Metastatic Bone Pain

TELIX INVESTIGATION REMINDER: Bragar Eagel & Squire, P.C. Reminds Telix Pharmaceuticals Investors to Contact the Firm Regarding Ongoing Investigation on Behalf of Stockholders

Oct 15, 2025, 5:13 PM EDT - 2 months ago

TELIX INVESTIGATION REMINDER: Bragar Eagel & Squire, P.C. Reminds Telix Pharmaceuticals Investors to Contact the Firm Regarding Ongoing Investigation on Behalf of Stockholders

Telix Pharmaceuticals Enters Q4 On Strong Footing With Stabilized Pricing Pressures, Upgraded Annual Sales Guidance

Oct 14, 2025, 2:11 PM EDT - 2 months ago

Telix Pharmaceuticals Enters Q4 On Strong Footing With Stabilized Pricing Pressures, Upgraded Annual Sales Guidance

Telix Reports US$206M Revenue, FY 2025 Guidance Upgraded

Oct 14, 2025, 2:22 AM EDT - 2 months ago

Telix Reports US$206M Revenue, FY 2025 Guidance Upgraded

CMS Grants Transitional Pass-Through Status for Gozellix

Sep 23, 2025, 10:15 AM EDT - 3 months ago

CMS Grants Transitional Pass-Through Status for Gozellix

Telix Pharmaceuticals Limited (TLX) Hits Another Roadblock After SEC Subpoena, Shares Fall Again -- Hagens Berman

Sep 19, 2025, 8:30 AM EDT - 3 months ago

Telix Pharmaceuticals Limited (TLX) Hits Another Roadblock After SEC Subpoena, Shares Fall Again -- Hagens Berman

Telix Pharmaceuticals Limited (TLX) Hits Another Roadblock After SEC Subpoena, Shares Fall Again – Hagens Berman

Sep 11, 2025, 2:32 PM EDT - 3 months ago

Telix Pharmaceuticals Limited (TLX) Hits Another Roadblock After SEC Subpoena, Shares Fall Again – Hagens Berman

Telix Pharmaceuticals Limited (TLX) Presents At H.C. Wainwright 27th Annual Global Investment Conference Transcript

Sep 9, 2025, 7:33 PM EDT - 3 months ago

Telix Pharmaceuticals Limited (TLX) Presents At H.C. Wainwright 27th Annual Global Investment Conference Transcript

Telix Doses First Patient in Phase 3 BiPASS Trial: PSMA-PET Imaging for Prostate Cancer Diagnosis

Sep 9, 2025, 7:00 PM EDT - 3 months ago

Telix Doses First Patient in Phase 3 BiPASS Trial: PSMA-PET Imaging for Prostate Cancer Diagnosis

Telix Pharmaceuticals Limited (TLX) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript

Sep 8, 2025, 7:28 PM EDT - 3 months ago

Telix Pharmaceuticals Limited (TLX) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript

Telix Pharmaceuticals: Roadblocks Piling Up, But They're Not Insurmountable

Aug 29, 2025, 1:57 PM EDT - 4 months ago

Telix Pharmaceuticals: Roadblocks Piling Up, But They're Not Insurmountable

Telix Gets Second FDA Rejection For Kidney Cancer Drug

Aug 28, 2025, 1:08 PM EDT - 4 months ago

Telix Gets Second FDA Rejection For Kidney Cancer Drug

US FDA seeks more information on Telix Pharma's diagnostic drug for kidney cancer

Aug 27, 2025, 9:58 PM EDT - 4 months ago

US FDA seeks more information on Telix Pharma's diagnostic drug for kidney cancer

Telix Pharmaceuticals Limited (TLX) Shares Fall Amid SEC Subpoena -- Hagens Berman

Aug 26, 2025, 4:22 PM EDT - 4 months ago

Telix Pharmaceuticals Limited (TLX) Shares Fall Amid SEC Subpoena -- Hagens Berman

Telix to Present at the Morgan Stanley 23rd Annual Global Healthcare Conference and H.C. Wainwright 27th Annual Global Investment Conference

Aug 26, 2025, 7:00 AM EDT - 4 months ago

Telix to Present at the Morgan Stanley 23rd Annual Global Healthcare Conference and H.C. Wainwright 27th Annual Global Investment Conference

TLX Investors Have Opportunity to Join Telix Pharmaceuticals Limited Fraud Investigation with the Schall Law Firm

Aug 25, 2025, 3:20 AM EDT - 4 months ago

TLX Investors Have Opportunity to Join Telix Pharmaceuticals Limited Fraud Investigation with the Schall Law Firm

Telix Pharmaceuticals Limited (TLX) Q2 2025 Earnings Call Transcript

Aug 22, 2025, 12:23 PM EDT - 4 months ago

Telix Pharmaceuticals Limited (TLX) Q2 2025 Earnings Call Transcript